ProNAi Therapeutics (DNAI) : 4 analysts are covering ProNAi Therapeutics (DNAI) and their average rating on the stock is 2.5, which is read as a Buy. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
ProNAi Therapeutics (DNAI) : Average target price received by ProNAi Therapeutics (DNAI) is $3.75 with an expected standard deviation of $1.06. The most aggressive target on the stock is $5, whereas the most downbeat target is $3. 2 financial analysts are currently covering the stock.
Company shares have received an average consensus rating of Hold for the current week
ProNAi Therapeutics (NASDAQ:DNAI): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.88 and $1.86 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.99. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.97, notching a gain of 4.79% for the day. The total traded volume was 765,283 . The stock had closed at $1.88 on the previous day.
ProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company develops and commercializes a portfolio of therapeutics based on its deoxyribonucleic acid interference (DNAi) technology platform for patients with cancer and hematological diseases. The Companys lead DNAi product candidate, PNT2258, treat cancers that overexpress BCL2, an oncogene known to be dysregulated in many types of cancer. Its platform consists of two components: Rationally-Designed DNAi Oligonucleotides and Lipid Nanoparticle (LNP) Delivery Technology. The Company has conducted two clinical trials for PNT2258: a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkins lymphoma (NHL). It has initiated Wolverine, a Phase II trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.